{"name":"SUGEN","slug":"sugen","ticker":"","exchange":"","domain":"","description":"SUGEN (Sugen) was a drug discovery company focused on development of protein kinase inhibitors. It was founded in 1991, and shut down in 2003, after developing the pioneering kinase inhibitor drug sunitinib (Sutent).","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2023-05-18","type":"patent","source":"Business Standard","summary":"Delhi HC relies on WayBack Machine evidence in patent infringement case - Business Standard","headline":"Delhi HC relies on WayBack Machine evidence in patent infringement case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9faXAzcVR2MW1idUlNbmZBTjNmeEtXUENHbVd1SmlRbWY3aVItRzVZSlgtOEFkVW1WOTZsMjVHRU92V2NIY3I0THhnN1FuQlR2SU9JV0hn?oc=5","date":"2017-12-25","type":"pipeline","source":"Nature","summary":"Sugen's strategy: a signal for P&U purchase - Nature","headline":"Sugen's strategy: a signal for P&U purchase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNY3k4Zm1xc3BWaXprblg0eDljMjNJT0RVWTF6Y2dFaTJLQ0VaLU5DLTNYZ0NuVTU1ZjBuMkhzU19aNWxsQkRNLTZLVzFfdEpfODRvSjJrWVdZVGprWE1pSVlCaGx1bFk5bS16Tk1PYkJRTGdEdGZ3dFM4cFJ2SkpmYnhaOVM0S3BjOHUzb3FfLUEtcEdUNERTNkk1VzV2U1dNYzJqbA?oc=5","date":"2017-05-04","type":"pipeline","source":"Fierce Pharma","summary":"Pfizer faces renewed bid for Xalkori royalties as appeals panel revives NYU lawsuit - Fierce Pharma","headline":"Pfizer faces renewed bid for Xalkori royalties as appeals panel revives NYU lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFAydmliM0dPakJueXNtU3hoUjRVc3RDVjZTTjN4ekptYjJDeDNxRWxGXzdKY3NIQjlHbDhmY3JZVWExN2YzbXZmdUNMLUEzWUQ2SUxxbzJYUklHdGZ5?oc=5","date":"2007-11-29","type":"pipeline","source":"Power Technology","summary":"Sugen 1,100MW CCGT, Akhakhol, Gujarat - Power Technology","headline":"Sugen 1,100MW CCGT, Akhakhol, Gujarat","sentiment":"neutral"},{"date":"1999-08-16","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"1999-08-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"1999-06-25","type":"earnings","source":"SEC EDGAR","summary":"SC 13D filed with SEC: SCHEDULE 13D","headline":"SC 13D Filing","sentiment":"neutral"},{"date":"1999-06-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"1999-05-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":null,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":null,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}